Cited by 37Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and TreatmentsOccupational and environmental lung diseases

p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling

Open access
Nagaraja, M.R., Tiwari, Nivedita, Shetty, Shwetha K., Marudamuthu, Amarnath S., Fan, Liang, Ostrom, Rennolds S., Fu, Jian, Gopu, Venkadesaperumal +3 more·2018·The American Journal of Pathology

Abstract

Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease. A cardinal feature of the pathogenesis of IPF is excessive extracellular matrix deposition attributable to proliferation of activated fibrotic lung fibroblasts (fLfs). To assess the underlying mechanism, we analyzed the status of the tumor suppressor protein p53 in fLfs from the lungs of IPF patients or mice with bleomycin-induced established PF. We report that basal expression of p53 is markedly reduced in fLfs. Forced expression of caveolin-1 in fLfs increased basal p53 and reduced profibrogenic proteins, including collagen-1. Transduction of fLfs with adenovirus expressing p53 reduced expression of these proteins. Conversely, inhibition of baseline p53 in control lung fibroblasts from lung tissues increased profibrogenic protein expression. Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice. Furthermore, treatment of fLfs or fibrotic lung tissues with caveolin-1 scaffolding domain peptide (CSP) or its fragment, CSP7, restored p53 and reduced profibrogenic proteins. Treatment of wild-type mice with i.p. CSP or CSP7 resolved bleomycin-induced PF. These peptides failed to resolve PF in inducible conditional knockout mice lacking p53 in fLfs, indicating the induction of baseline fLf p53 as the basis of the antifibrotic effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2018.07.005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cav-1 expression in pulmonary fibroblasts and alveolar epithelial cells is decreased in transgenic and rodent bleomycin models of lung injury and in the lungs of patients with IPF.

    “Cav-1 expression in pulmonary fibroblasts and alveolar epithelial cells is decreased in transgenic and rodent bleomycin models of lung injury and in the lungs of patients with IPF10–12.”

    From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [11]

    The Discussion and Figure 2 caption report reduced Cav1 in lung fibroblasts from patients with IPF and mice with bleomycin-induced fibrosis (page not specified in our copy). The Discussion instead describes increased Cav1 expression in injured alveolar epithelial cells; our copy does not establish the claimed decrease in those cells or in a transgenic injury model. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • Augmentation of endogenous Cav-1 levels and supplementation of exogenous caveolin scaffolding domain peptide have been shown to suppress lung fibrosis.

    “Augmentation of endogenous Cav-1 levels and supplementation of exogenous caveolin scaffolding domain (CSD) peptide have been shown to suppress lung fibrosis7,10,11,13,14.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006, 103:13180e13185
  2. Aoshiba K, Nagai A: Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 2003, 1:21
  3. Margaritopoulos GA, Vasarmidi E, Antoniou KM: Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid 2016, 11:11e22
  4. Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N: Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016, 5:78
  5. Kendall RT, Feghali-Bostwick CA: Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 2014, 5:123
  6. Todd NW, Luzina IG, Atamas SP: Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5:11
  7. Markowski DN, Helmke BM, Radtke A, Froeb J, Belge G, Bartnitzke S, Wosniok W, Czybulka-Jachertz I, Deichert U, Bullerdiek J: Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium. BMC Womens Health 2012, 12:2
  8. Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8

Cited by

Sorted by citations

Authors
Nagaraja, M. R., Tiwari, N., Shetty, S. K., Marudamuthu, A. S., Fan, L., Ostrom, R. S., Fu, J., Gopu, V., Radhakrishnan, V., Idell, S., & Shetty, S.
Affiliations
  • The University of Texas Health Science Center at Tyler (US)
  • Chapman University (US)
  • University of Kentucky (US)
Corresponding author
Shetty, Sreerama
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2018-10
Volume
188
Issue
10
Pages
2207-2222
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2892840122
Cited by
37
References
2
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 5 · 2019: 2
FWCI
1.70
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Chapman University Digital Commons (Chapman University) (submittedVersion)
Funders
  • Flight Attendant Medical Research Institute (150063)
  • National Institutes of Health (R01HL133067-01, R21ES025815)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
p53, idiopathic pulmonary fibrosis, lung fibroblasts, caveolin-1, bleomycin-induced lung fibrosis, extracellular matrix deposition, collagen-1, antifibrotic therapy
MeSH terms
Animals, Antibiotics, Antineoplastic, Bleomycin, Fibroblasts, Humans, Mice, Inbred C57BL, Peptide Fragments, Transduction, Genetic, Tumor Suppressor Protein p53, Caveolin 1, Idiopathic Pulmonary Fibrosis, Airway Remodeling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review